Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.91 |
| ▸ | TP53 | P04637 | 6/20 | 0.91 |
| ▸ | LMNA | P02545 | 4/20 | 0.91 |
| ▸ | RAB9A | P51151 | 9/20 | 0.86 |
| ▸ | NPC1 | O15118 | 7/20 | 0.86 |
| ▸ | HTT | P42858 | 3/20 | 0.86 |
| ▸ | HPGD | P15428 | 3/20 | 0.86 |
| ▸ | GAA | P10253 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.86 |
| ▸ | TSHR | P16473 | 1/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.79 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 4/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.79 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12259162 | 0.88 | NPC1 (0.90) | SMN1; SMN2TP53LMNARAB9ANPC1 | |
| SCHEMBL6633618 | 0.87 | KMT2A (0.89) | SMN1; SMN2TP53LMNARAB9ANPC1 | |
| SCHEMBL12167627 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2TP53LMNARAB9ANPC1 | |
| SCHEMBL12167788 | 0.84 | SMN1; SMN2 (0.79) | SMN1; SMN2TP53LMNARAB9ANPC1 | |
| SCHEMBL6637453 | 0.83 | PTPN2 (0.77) | SMN1; SMN2TP53LMNARAB9ANPC1 | |
| SCHEMBL14567962 | 0.83 | SMN1; SMN2 (0.75) | SMN1; SMN2TP53LMNARAB9ANPC1 | |
| SCHEMBL580225 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2TP53LMNARAB9ANPC1 | |
| SCHEMBL2997673 | 0.82 | RAB9A (1.00) | SMN1; SMN2TP53LMNARAB9ANPC1 | |
| SCHEMBL12167652 | 0.82 | TDP1 (0.71) | SMN1; SMN2TP53LMNARAB9ANPC1 | |
| SCHEMBL19419914 | 0.82 | NPC1 (0.78) | SMN1; SMN2TP53LMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973735-B1 | POLYAROMATIC ANTIVIRAL COMPOSITIONS | UPJOHN CO (US) | 2003-01-29 | — | — | EP | claimed |
| US-5958983-A | NOVEL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST HERPES, TOPICAL ADMINISTRATION THEM TO TREAT PATIENTS WITH HERPES; WORK BY INHIBITING THE INITIATION OF HERPES VIRAL DNA SYNTHESIS IN HOST CELLS | PHARMACIA & UPJOHN COMPANY (US) | 1999-09-28 | — | — | US | claimed |
| US-8268885-B2 | Entry inhibitors of the HIV virus | JANSSEN R&D IRELAND (IE) | 2012-09-18 | — | — | US | disclosed |
| EP-1667675-B1 | ENTRY INHIBITORS OF THE HIV VIRUS | TIBOTEC PHARM LTD (IE) | 2011-11-09 | — | — | EP | disclosed |
| US-20070066623-A1 | Entry inhibitors of the hiv virus | JANSSEN R&D IRELAND (IE) | 2007-03-22 | — | — | US | disclosed |
| EP-0973735-B1 | POLYAROMATIC ANTIVIRAL COMPOSITIONS | UPJOHN CO (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1148048-A2 | Polyaromatic antiviral compositions | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6147116-A | TOPICALLY ADMINISTERING BENZENE DERIVATIVE SUBSTITUTED WITH UREIDO-, THIOUREIDO, AND/OR SULFONAMIDO GROUPS TO TREAT HERPES | PHARMACIA & UPJOHN COMPANY (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0973735-A2 | POLYAROMATIC ANTIVIRAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5958983-A | NOVEL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST HERPES, TOPICAL ADMINISTRATION THEM TO TREAT PATIENTS WITH HERPES; WORK BY INHIBITING THE INITIATION OF HERPES VIRAL DNA SYNTHESIS IN HOST CELLS | PHARMACIA & UPJOHN COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1998045259-A2 | POLYAROMATIC ANTIVIRAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066623-A1 | Entry inhibitors of the hiv virus | HAVCR2, CCR5, SAMHD1 | SMN1; SMN2 4809/4885TP53 3579/4885LMNA 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.